Ann M Leen

List of Publications by Year
in descending order

81 papers	4,951 citations	186265 28 h-index	138484 58 g-index
81 all docs	81 docs citations	81 times ranked	4677 citing authors

#	Article	IF	Citations
1	Monoculture-derived T lymphocytes specific for multiple viruses expand and produce clinically relevant effects in immunocompromised individuals. Nature Medicine, 2006, 12, 1160-1166.	30.7	536
2	Multicenter study of banked third-party virus-specific T cells to treat severe viral infections after hematopoietic stem cell transplantation. Blood, 2013, 121, 5113-5123.	1.4	507
3	Off-the-Shelf Virus-Specific T Cells to Treat BK Virus, Human Herpesvirus 6, Cytomegalovirus, Epstein-Barr Virus, and Adenovirus Infections After Allogeneic Hematopoietic Stem-Cell Transplantation. Journal of Clinical Oncology, 2017, 35, 3547-3557.	1.6	367
4	Activity of Broad-Spectrum T Cells as Treatment for AdV, EBV, CMV, BKV, and HHV6 Infections after HSCT. Science Translational Medicine, 2014, 6, 242ra83.	12.4	357
5	Cytotoxic T lymphocyte therapy with donor T cells prevents and treats adenovirus and Epstein-Barr virus infections after haploidentical and matched unrelated stem cell transplantation. Blood, 2009, 114, 4283-4292.	1.4	311
6	Complete responses of relapsed lymphoma following genetic modification of tumor-antigen presenting cells and T-lymphocyte transfer. Blood, 2007, 110, 2838-2845.	1.4	266
7	Improving T Cell Therapy for Cancer. Annual Review of Immunology, 2007, 25, 243-265.	21.8	233
8	Improving Chimeric Antigen Receptor-Modified T Cell Function by Reversing the Immunosuppressive Tumor Microenvironment of Pancreatic Cancer. Molecular Therapy, 2017, 25, 249-258.	8.2	217
9	Reversal of Tumor Immune Inhibition Using a Chimeric Cytokine Receptor. Molecular Therapy, 2014, 22, 1211-1220.	8.2	145
10	Fine-tuning the CAR spacer improves T-cell potency. OncoImmunology, 2016, 5, e1253656.	4.6	137
11	Conserved CTL epitopes on the adenovirus hexon protein expand subgroup cross-reactive and subgroup-specific CD8+ T cells. Blood, 2004, 104, 2432-2440.	1.4	129
12	Adenovirus as an emerging pathogen in immunocompromised patients. British Journal of Haematology, 2005, 128, 135-144.	2.5	129
13	Identification of Hexon-Specific CD4 and CD8 T-Cell Epitopes for Vaccine and Immunotherapy. Journal of Virology, 2008, 82, 546-554.	3.4	129
14	Adoptive immunotherapy for primary immunodeficiency disorders with virus-specific T lymphocytes. Journal of Allergy and Clinical Immunology, 2016, 137, 1498-1505.e1.	2.9	117
15	Kinetics of Tumor Destruction by Chimeric Antigen Receptor-modified T Cells. Molecular Therapy, 2014, 22, 623-633.	8.2	113
16	Enhancing the Potency and Specificity of Engineered T Cells for Cancer Treatment. Cancer Discovery, 2018, 8, 972-987.	9.4	93
17	CAR T cell therapy for breast cancer: harnessing the tumor milieu to drive T cell activation. , 2018, 6, 34.		85
18	Generation of Tumor Antigen-Specific T Cell Lines from Pediatric Patients with Acute Lymphoblastic Leukemiaâ€"Implications for Immunotherapy. Clinical Cancer Research, 2013, 19, 5079-5091.	7.0	81

#	Article	IF	Citations
19	Cytotoxic T Lymphocytes Simultaneously Targeting Multiple Tumor-associated Antigens to Treat EBV Negative Lymphoma. Molecular Therapy, 2011, 19, 2258-2268.	8.2	80
20	Vaccination Targeting Native Receptors to Enhance the Function and Proliferation of Chimeric Antigen Receptor (CAR)-Modified T Cells. Clinical Cancer Research, 2017, 23, 3499-3509.	7.0	76
21	Optimizing the production of suspension cells using the G-Rex â€œMâ€•series. Molecular Therapy - Methods and Clinical Development, 2014, 1, 14015.	4.1	71
22	Antiviral Tâ€cell therapy. Immunological Reviews, 2014, 258, 12-29.	6.0	58
23	General and Virus-Specific Immune Cell Reconstitution after Double Cord Blood Transplantation. Biology of Blood and Marrow Transplantation, 2015, 21, 1284-1290.	2.0	51
24	Adenoviral Infections in Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2006, 12, 243-251.	2.0	50
25	Is cancer gene therapy an empty suit?. Lancet Oncology, The, 2013, 14, e447-e456.	10.7	48
26	Clinical effects of administering leukemia-specific donor T cells to patients with AML/MDS after allogeneic transplant. Blood, 2021, 137, 2585-2597.	1.4	38
27	Cytotoxic T lymphocytes as immuneâ€therapy in haematological practice. British Journal of Haematology, 2008, 143, 169-179.	2.5	35
28	Challenges of T cell therapies for virus-associated diseases after hematopoietic stem cell transplantation. Expert Opinion on Biological Therapy, 2010, 10, 337-351.	3.1	31
29	T-Cell Therapy for Lymphoma Using Nonengineered Multiantigen-Targeted T Cells Is Safe and Produces Durable Clinical Effects. Journal of Clinical Oncology, 2021, 39, 1415-1425.	1.6	30
30	Selectively targeting myeloid-derived suppressor cells through TRAIL receptor 2 to enhance the efficacy of CAR T cell therapy for treatment of breast cancer. , 2021, 9, e003237.		29
31	Systemic Inflammatory Response Syndrome After Administration of Unmodified T Lymphocytes. Molecular Therapy, 2014, 22, 1134-1138.	8.2	28
32	Graft Versus Leukemia Response Without Graft-versus-host Disease Elicited By Adoptively Transferred Multivirus-specific T-cells. Molecular Therapy, 2015, 23, 179-183.	8.2	28
33	Infusion of cytotoxic T lymphocytes for the treatment of viral infections in hematopoetic stem cell transplant patients. Current Opinion in Infectious Diseases, 2018, 31, 292-300.	3.1	27
34	Rapid generation of multivirus-specific T lymphocytes for the prevention and treatment of respiratory viral infections. Haematologica, 2020, 105, 235-243.	3.5	26
35	The safety and clinical effects of administering a multiantigen-targeted T cell therapy to patients with multiple myeloma. Science Translational Medicine, 2020, 12, .	12.4	25
36	A New Method for Reactivating and Expanding T Cells Specific for Rhizopus oryzae. Molecular Therapy - Methods and Clinical Development, 2018, 9, 305-312.	4.1	24

#	Article	IF	Citations
37	Contact-activated Monocytes: Efficient Antigen Presenting Cells for the Stimulation of Antigen-specific T cells. Journal of Immunotherapy, 2007, 30, 96-107.	2.4	23
38	Immunologic Profiling of Human Metapneumovirus for the Development of Targeted Immunotherapy. Journal of Infectious Diseases, 2017, 216, 678-687.	4.0	23
39	Characterizing the Cellular Immune Response to Parainfluenza Virus 3. Journal of Infectious Diseases, 2017, 216, 153-161.	4.0	19
40	Engineered T cells for cancer treatment. Cytotherapy, 2014, 16, 713-733.	0.7	18
41	Expanding CAR T cells in human platelet lysate renders T cells with in vivo longevity. , 2019, 7, 330.		18
42	Epstein-Barr Virus (EBV)-derived BARF1 encodes CD4- and CD8-restricted epitopes as targets for T-cell immunotherapy. Cytotherapy, 2019, 21, 212-223.	0.7	16
43	Preventing stem cell transplantation-associated viral infections using T-cell therapy. Immunotherapy, 2015, 7, 793-810.	2.0	15
44	Asian Elephant T Cell Responses to Elephant Endotheliotropic Herpesvirus. Journal of Virology, 2018, 92, .	3.4	13
45	Donor-derived multiple leukemia antigenâ€“specific T-cell therapy to prevent relapse after transplantÂin patients with ALL. Blood, 2022, 139, 2706-2711.	1.4	13
46	Accelerating immune reconstitution after hematopoietic stem cell transplantation. Clinical and Translational Immunology, 2014, 3, e11.	3.8	11
47	Identification of protective T-cell antigens for smallpox vaccines. Cytotherapy, 2020, 22, 642-652.	0.7	10
48	A phase I/II study combining a TMZ-CD40L/4-1BBL-armed oncolytic adenovirus and nab-paclitaxel/gemcitabine chemotherapy in advanced pancreatic cancer: An interim report.. Journal of Clinical Oncology, 2020, 38, 716-716.	1.6	9
49	A phase I trial targeting advanced or metastatic pancreatic cancer using a combination of standard chemotherapy and adoptively transferred nonengineered, multiantigen specific T cells in the first-line setting (TACTOPS).. Journal of Clinical Oncology, 2020, 38, 4622-4622.	1.6	9
50	Toward Functional Immune Monitoring in Allogeneic Stem Cell Transplant Recipients. Biology of Blood and Marrow Transplantation, 2020, 26, 911-919.	2.0	8
51	Immune-Based Therapies Targeting Mage-A4 for Relapsed/Refractory Hodgkin's Lymphoma After Stem Cell Transplant.. Blood, 2009, 114, 4089-4089.	1.4	7
52	Adoptive T cell therapy for the treatment of viral infections. Annals of Translational Medicine, 2015, 3, 278.	1.7	7
53	Multi-antigen-targeted T-cell therapy to treat patients with relapsed/refractory breast cancer. Therapeutic Advances in Medical Oncology, 2022, 14, 175883592211071.	3.2	6
54	Evaluation of cyclin A1â€“specific T cells as a potential treatment for acute myeloid leukemia. Blood Advances, 2020, 4, 387-397.	5.2	4

#	Article	IF	Citations
55	Generation of Multi-Antigen Specific T Cells for Adoptive Immunotherapy of Myeloid Leukemia and Identification of MHC Class I and II-Restricted Peptides for WT1, Proteinase 3 and Human Neutrophil Elastase. Blood, 2011, 118, 2985-2985.	1.4	4
56	Adoptive immunotherapy for herpesviruses. , 2007, , 1318-1331.		2
57	Overcoming the breast tumor microenvironment by targeting MDSCs through CAR-T cell therapy.. Journal of Clinical Oncology, 2021, 39, 1032-1032.	1.6	2
58	Administration of Most Closely HLA-Matched Multivirus-Specific T Cells for the Treatment of EBV, CMV, AdV, HHV6, and BKV Post Allogeneic Hematopoietic Stem Cell Transplant. Blood, 2016, 128, 501-501.	1.4	2
59	Using Allogeneic, Off-the-Shelf, Sars-Cov-2-Specific T Cells to Treat High Risk Patients with COVID-19. Blood, 2020, 136, 5-5.	1.4	2
60	Allogeneic Virus-Specific T Cells with HLA Alloreactivity Do Not Produce Graft-Versus-Host Disease In Human Subjects. Blood, 2010, 116, 1252-1252.	1.4	1
61	Combining Oncolytic Vaccinia Virotherapy with Adoptive T Cell Therapy,. Blood, 2011, 118, 4042-4042.	1.4	1
62	Safety and Preliminary Efficacy of "Ready to Administer" Cytomegalovirus (CMV)-Specific T Cells for the Treatment of Patients with Refractory CMV Infection. Blood, 2016, 128, 388-388.	1.4	1
63	Retrovirus-Transduced T Cell Blasts Have Not Only Antigen-Presenting Capabilities but Also Suppressor Regulatory T Cell-Inducing Capability.. Blood, 2004, 104, 3855-3855.	1.4	0
64	The Clinical Use of Donor-Derived Virus-Specific Cytotoxic T Lymphocytes Reactive Against Cytomegalovirus (CMV), Adenovirus and Epstein Barr Virus (EBV).. Blood, 2005, 106, 81-81.	1.4	0
65	Complete Tumor Responses in Lymphoma Patients Who Receive Autologous Cytotoxic T Lymphocytes Targeting EBV Latent Membrane Proteins. Blood, 2008, 112, 230-230.	1.4	0
66	Multivirus-Specific T Cell Immunotherapy to Prevent or Treat Infections of Stem Cell Transplant Recipients.. Blood, 2008, 112, 2207-2207.	1.4	0
67	The â€œSide-Populationâ€•of Human Lymphoma Cells Have Increased Chemo-Resistance, Stem-Cell Like Properties and Are Potential Targets for Immunotherapy. Blood, 2008, 112, 2620-2620.	1.4	0
68	Rapid Generation of Antigen-Specific T Cells for Pre-Clinical and Clinical Applications Using a Novel Mini Cell Bioreactor. Blood, 2008, 112, 208-208.	1.4	0
69	Exploiting Cytokine Secretion to Rapidly Produce Multivirus-Specific T Cells for Adoptive Immunotherapy. Blood, 2008, 112, 4594-4594.	1.4	0
70	Cytotoxic T Lymphocytes (CTL) Specific for Adenovirus and CMV Can Be Generated from Umbilical Cord Blood for Adoptive Immunotherapy. Blood, 2008, 112, 3505-3505.	1.4	0
71	Safely Improving the in Vivo Survival of Tumor Specific Cytotoxic T Lymphocytes by Co-Transfer of IL7 Receptor Alpha Chain and icaspase9. Blood, 2008, 112, 3534-3534.	1.4	0
72	Cytotoxic T Lymphocytes (CTL) Specific for CMV, Adenovirus, and EBV Can Be Generated From Naive T Cells for Adoptive Immunotherapy.. Blood, 2009, 114, 504-504.	1.4	0

#	Article	IF	Citations
73	Detection and Ex Vivo Expansion of Anti-Viral T Cells Isolated From Recipients of Unrelated Umbilical Cord Blood Transplant.. Blood, 2009, 114, 2245-2245.	1.4	0
74	Adverse Events Following Infusion of T Cells for Adoptive Immunotherapy: A 10 Year Experience.. Blood, 2009, 114, 3212-3212.	1.4	0
75	Despite Absence of Measurable Immune Responses against Adenovirus in the First 100 Days After Unrelated Umbilical Cord Blood Transplant in Vitro amplification Strategies Can Unveil Hexon and Penton-Specific Immunity.. Blood, 2009, 114, 4640-4640.	1.4	0
76	Towards Phase 2/3 Trials for Epstein - Barr Virus (EBV)-Associated Malignancies,. Blood, 2011, 118, 4043-4043.	1.4	0
77	Human Papillomavirus Type 16 (HPV16) E6/E7-Specific Cytotoxic T Lymphocytes (CTLs) for Immunotherapy of HPV-Associated Malignancies. Blood, 2011, 118, 1913-1913.	1.4	0
78	Human papillomavirus type 16 (HPV16) E6/E7-specific cytotoxicÂT lymphocytes (CTL) for immunotherapy of HPV-associated cancer (Ca).. Journal of Clinical Oncology, 2012, 30, 2558-2558.	1.6	0
79	Administration of Most Closely HLA-Matched Multivirus-Specific T Cells for the Treatment of EBV, CMV, AdV, HHV6, and BKV Post Allogeneic Hematopoietic Stem Cell Transplant. Blood, 2015, 126, 622-622.	1.4	0
80	Adoptively-Transferred EBV-Specific T Cells to Prevent or Treat EBV-Related Lymphoproliferative Disease in Allogeneic HSCT Recipients - a Single Center Experience Spanning 22 Years. Blood, 2015, 126, 1926-1926.	1.4	0
81	Donor-Derived Adoptive T-Cell Therapy Targeting Multiple Tumor Associated Antigens to Prevent Post-Transplant Relapse in Patients with ALL. Blood, 2021, 138, 471-471.	1.4	0